Glonghui, July 14 丨 Nomura released a report saying that it maintained the Fuhong Hanlin-B (2696.HK) “buy” rating, raised the target price from HK$52.4 to HK$76.7, and raised the company's revenue forecasts for 2020 to 2022 to 935 million, 2,557 million and 3,839 million yuan respectively to reflect the expansion of production capacity and approval of new generic drugs for trastuzumab antibiotics earlier than expected. It is expected that the company will achieve balance of payments as early as 2022. The stock is now at HK$61, with a total market capitalization of HK$33.1 billion.